Viking Therapeutics, Inc. (NASDAQ:VKTX) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Thursday.

A number of other research analysts also recently issued reports on VKTX. Maxim Group set a $5.00 price target on shares of Viking Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 10th. HC Wainwright restated a “buy” rating and issued a $7.00 price target (up from $5.00) on shares of Viking Therapeutics in a research report on Monday, July 17th.

Viking Therapeutics (NASDAQ:VKTX) traded up 6.67% on Thursday, reaching $1.12. 579,917 shares of the company’s stock were exchanged. Viking Therapeutics has a 1-year low of $0.88 and a 1-year high of $1.70. The firm’s market capitalization is $31.02 million. The stock’s 50 day moving average price is $1.05 and its 200 day moving average price is $1.22.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.02. On average, analysts expect that Viking Therapeutics will post ($0.82) earnings per share for the current year.

WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/09/07/viking-therapeutics-inc-vktx-upgraded-to-sell-at-valuengine.html.

A number of large investors have recently modified their holdings of the stock. Sio Capital Management LLC lifted its position in Viking Therapeutics by 53.3% in the 3rd quarter. Sio Capital Management LLC now owns 849,905 shares of the biotechnology company’s stock valued at $1,191,000 after purchasing an additional 295,523 shares during the last quarter. Renaissance Technologies LLC lifted its position in Viking Therapeutics by 62.9% in the 1st quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock valued at $388,000 after purchasing an additional 102,600 shares during the last quarter. Virtu KCG Holdings LLC bought a new stake in Viking Therapeutics in the 2nd quarter valued at about $124,000. Finally, GRT Capital Partners L.L.C. lifted its position in Viking Therapeutics by 187.8% in the 4th quarter. GRT Capital Partners L.L.C. now owns 94,978 shares of the biotechnology company’s stock valued at $113,000 after purchasing an additional 61,978 shares during the last quarter. Hedge funds and other institutional investors own 5.67% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.